Showing results (1281-1290 of 1,308) with videos related to

Sort By:
Pageof 131
Arthritis Research & Therapy|October 20, 2023
Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaborationLouise Linde, Lykke M Ørnbjerg, Simon H Rasmussen, et al.
RMD Open|September 20, 2020
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaborationBrigitte Michelsen, Ulf Lindström, Catalin Codreanu, et al.
Seminars in Arthritis and Rheumatism|August 19, 2022
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaborationLykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
International Journal of Cancer|May 6, 2009
Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohortNina Føns Johnsen, Anne Tjønneland, Birthe L R Thomsen, et al.
Seminars in Arthritis and Rheumatism|February 1, 2024
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practiceSara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, et al.
Joint Bone Spine|November 28, 2024
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritisMarion Pons, Stylianos Georgiadis, Mikkel Østergaard, et al.
The Lancet Regional Health. Europe|August 21, 2023
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Arthritis Care & Research|January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European CountriesBrigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
Arthritis Research & Therapy|January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registriesAdrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Pageof 131